Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Wall Street Analysts. Tyra Biosciences, Inc. (NASDAQ:TYRA) is one of the most promising stocks on our list.

TheFly reported on June 17 that Oppenheimer initiated coverage of TYRA with an Outperform rating and a $50 price target. The firm highlighted TYRA’s upcoming clinical milestones, particularly the expected three-month complete response data from the SURF302 study in induction-refractory non-muscle invasive bladder cancer, anticipated in August 2026. Following discussions with company management, Oppenheimer expressed increased confidence in TYRA’s outlook. The firm also noted the company’s strong cash position of $383.5 million, expected to support operations into the second half of 2028, while viewing its oral treatment approach as a potential advantage in a disease area marked by repeated procedures and recurrence challenges.

Is Tyra Biosciences, Inc. (TYRA) Stock a Biotech Opportunity Ahead of Key SURF302 Trial Data?

Earlier on May 13, Tyra Biosciences, Inc. (NASDAQ:TYRA) released its first quarter 2026 financial results, reporting increased investment in clinical development programs. Research and development expenses reached $33.5 million for the quarter ended March 31, 2026, compared with $25.0 million in the prior-year period, mainly due to ongoing dabogratinib activities, including the BEACH301 and SURF302 trials and preparations for SURF303. General and administrative expenses rose to $8.5 million from $6.9 million, driven by higher personnel-related costs. The company reported a first-quarter net loss of $39.3 million, compared with a net loss of $28.1 million during the same period in 2025.

Tyra Biosciences, Inc. (NASDAQ:TYRA) is a clinical-stage biotechnology company developing precision medicines targeting FGFR biology to treat cancer and genetically defined diseases.

While we acknowledge the risk and potential of TYRA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than TYRA and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1